Cookie Notice

This site uses cookies. By continuing to browse this site, you are agreeing to our use of cookies. Review our cookies information for more details.

OK
skip to main content

Corticosteroid spray used as-needed for treating perennial allergic rhinitis

Published online: October 10, 2020

Moderate-to-severe allergic rhinitis is still a problem worldwide because of troublesome symptoms. Corticosteroid spray used daily is the standard treatment of moderate-to-severe perennial allergic rhinitis (PAR). However, the majority of patients use their medications as-needed when their symptoms are well controlled or partially controlled. The as-needed use of corticosteroid spray has never been studied in patients with PAR.

In a recent article published in The Journal of Allergy and Clinical Immunology: In Practice, Thongngarm and colleagues conducted a randomized clinical trial in which the participants with moderate-to-severe persistent perennial allergic rhinitis received 6 weeks of treatment with either regular daily corticosteroid spray (regular group) or 1 week of daily corticosteroid spray, followed by 5 more weeks of as-needed corticosteroid spray (as-needed group). The primary outcome was the improvement in the total nasal symptom score (TNSS) between the 2 groups over the 6-week treatment period.

Thongngarm and colleagues reported that both “as-needed” and “regular” use of corticosteroid spray had similar improvement in nasal symptoms and quality of life. The treatment effect was less sustained with as-needed use. The cumulative dose of corticosteroid spray in the as-needed group was half that of the regular group. Adverse events were mild and comparable in both groups.

The researchers concluded that as-needed corticosteroid spray, at half of the total dose exposure, was similar to regular use in improving nasal symptoms and quality of life. They suggested that patients with moderate-to-severe persistent perennial allergic rhinitis should be treated with regular corticosteroid spray until symptoms are well-controlled, then the as-needed use could be a step-down treatment to keep a balance between acceptable symptom control versus long-term side effects and cost of treatment.

The Journal of Allergy and Clinical Immunology: In Practice is an official journal of the AAAAI, focusing on practical information for the practicing clinician.

Full Article